Ruthenium anticancer compounds: Challenges and expectations

被引：216
作者：
Bratsos, Ioannis
Jedner, Stephanie
Gianferrara, Teresa
Alessio, Enzo
机构：
[1] Univ Trieste, Dipartimento Sci Chim, I-34127 Trieste, Italy
[2] Univ Trieste, Dipartimento Sci Farmaceut, I-34127 Trieste, Italy
来源：
CHIMIA | 2007年 / 61卷 / 11期
关键词：
anticancer; antimetastatic; dimethylsulfoxide; medicinal inorganic; chemistry ruthenium;
D O I：
10.2533/chimia.2007.692
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Two ruthenium compounds, namely [ImH]trans-[RuCl4(Im)(dmso-S)] (NAMI-A, Im = imiclazole) and [IndH] trans-[RuCl4(Ind)(2)] (KP1019, Ind = indazole) have already completed phase I clinical trials as anticancer agents. They both have properties different from platinum anticancer drugs: for example, NAMI-A is selectively active against metastases of solid tumors. They show that in the field of anticancer metal drugs a new approach, based on targeted therapies, is possible. After a concise history of ruthenium anticancer compounds, this contribution will focus on ruthenium-dmso complexes and, in particular, on NAMI-A. Particular emphasis is given on the challenges that are inherent to this field: how to develop new anticancer ruthenium compounds and how to select new active compounds that manifest their anticancer activity through non-conventional mechanisms.
引用
收藏
页码：692 / 697
页数：6
相关论文
共 35 条
[1]   Synthesis and reactivity of Ru-, Os-, Rh-, and Ir-halide-sulfoxide complexes [J].
Alessio, E .
CHEMICAL REVIEWS, 2004, 104 (09) :4203-4242
[2]   Ruthenium antimetastatic agents [J].
Alessio, E ;
Mestroni, G ;
Bergamo, A ;
Sava, G .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (15) :1525-1535
[3]  
Alessio E, 2004, MET IONS BIOL SYST, V42, P323
[4]   SYNTHESIS AND CHARACTERIZATION OF 2 NEW CLASSES OF RUTHENIUM(III)-SULFOXIDE COMPLEXES WITH NITROGEN DONOR LIGANDS (L) - NA[TRANS-RUCL4(R2SO)(L)] AND MER,CIS-RUCL3(R2SO)(R2SO)(L) - THE CRYSTAL-STRUCTURE OF NA[TRANS-RUCL4(DMSO)(NH3)].2DMSO, NA[TRANS-RUCL4(DMSO)(IM)].H2O,ME2CO (IM=IMIDAZOLE) AND MER,CIS-RUCL3(DMSO)(DMSO)(NH3) [J].
ALESSIO, E ;
BALDUCCI, G ;
LUTMAN, A ;
MESTRONI, G ;
CALLIGARIS, M ;
ATTIA, WM .
INORGANICA CHIMICA ACTA, 1993, 203 (02) :205-217
[5]   Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis [J].
Ang, Wee Han ;
Daldini, Elisa ;
Scolaro, Claudine ;
Scopelliti, Rosario ;
Juillerat-Jeannerat, Lucienne ;
Dyson, Paul J. .
INORGANIC CHEMISTRY, 2006, 45 (22) :9006-9013
[6]   Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy [J].
Ang, Wee Han ;
Dyson, Paul J. .
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2006, (20) :4003-4018
[7]  
[Anonymous], METAL COMPLEXES CANC
[8]  
[Anonymous], 1999, TOP BIOL INORG CHEM
[9]   Ruthenium complexes can target determinants of tumour malignancy [J].
Bergamo, A. ;
Sava, G. .
DALTON TRANSACTIONS, 2007, 13 (13) :1267-1272
[10]   The unprecedented bridging coordination mode of 1,1-cyclobutane dicarboxylate (μ-cbdc-O,O′) stabilized by intramolecular hydrogen bonds in ruthenium(II) complexes [J].
Bratsos, I ;
Zangrando, E ;
Serli, B ;
Katsaros, N ;
Alessio, E .
DALTON TRANSACTIONS, 2005, (24) :3881-3885
1234